{"id":"chemotherapy-of-mfolfox6-or-folfiri","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Anemia"},{"rate":"20-30","effect":"Peripheral neuropathy (oxaliplatin-related)"},{"rate":"15-25","effect":"Mucositis"},{"rate":"30-40","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mFOLFOX6 combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin to inhibit thymidylate synthase and cause DNA crosslinking. FOLFIRI substitutes irinotecan (a topoisomerase I inhibitor) for oxaliplatin. Both regimens work synergistically to prevent cancer cell proliferation and induce apoptosis in colorectal and other solid tumors.","oneSentence":"mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:55.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Adjuvant treatment of stage III colorectal cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07498725","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"LARKSPUR BIOSCIENCES, INC.","startDate":"2026-05","conditions":"Neoplasms","enrollment":120},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT05846867","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-05-08","conditions":"Colorectal Cancer","enrollment":170},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT07042685","phase":"PHASE2","title":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT05332002","phase":"PHASE2","title":"sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-13","conditions":"Gastro-Intestinal Cancer","enrollment":38},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT06794086","phase":"PHASE3","title":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-04-10","conditions":"Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT04793958","phase":"PHASE3","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-24","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":461},{"nctId":"NCT06767007","phase":"PHASE2","title":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-06","conditions":"Unresectable Locally Recurrent Rectal Cancer","enrollment":31},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06590259","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-03-12","conditions":"Colorectal Cancer Liver Metastasis","enrollment":20},{"nctId":"NCT03135652","phase":"PHASE2","title":"Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation","status":"WITHDRAWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2017-08-01","conditions":"Radiotherapy, Colorectal Cancer, Liver Metastases","enrollment":""},{"nctId":"NCT05634590","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-12","conditions":"Metastatic Colorectal Cancer","enrollment":68},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT04734249","phase":"PHASE2","title":"Second-line Surufatinib Combined With Chemotherapy in Advanced CRC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2021-03","conditions":"Advanced Colorectal Cancer","enrollment":56},{"nctId":"NCT04337879","phase":"PHASE1, PHASE2","title":"A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-07-20","conditions":"Advanced Colorectal Cancer","enrollment":56},{"nctId":"NCT01803282","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-29","conditions":"Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer","enrollment":236},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT03686254","phase":"PHASE2, PHASE3","title":"The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-07-16","conditions":"Colorectal Neoplasms Malignant","enrollment":160},{"nctId":"NCT01888978","phase":"PHASE2","title":"Molecularly Tailored Therapy for Pancreas Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2012-12","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT01378143","phase":"PHASE2","title":"Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy","status":"COMPLETED","sponsor":"Oncozyme Pharma Inc.","startDate":"2011-03","conditions":"Colorectal Cancer","enrollment":53},{"nctId":"NCT00934882","phase":"PHASE1","title":"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-08","conditions":"Colorectal Neoplasms","enrollment":45},{"nctId":"NCT01189227","phase":"PHASE3","title":"Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2010-08","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":9},{"nctId":"NCT01564810","phase":"PHASE4","title":"Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2006-09","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2774,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mFOLFOX6"],"phase":"marketed","status":"active","brandName":"chemotherapy of mFOLFOX6 or FOLFIRI","genericName":"chemotherapy of mFOLFOX6 or FOLFIRI","companyName":"Xu jianmin","companyId":"xu-jianmin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}